NCT06682234View on ClinicalTrials.gov

Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Filovirus DiseasePostexposure Prophylaxis for Filovirus Disease

Interventions

DRUG

obeldesivir

Tablets administered orally

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY